These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8416286)

  • 21. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of paroxysmal nocturnal hemoglobinuria.
    Parker CJ
    Stem Cells; 1996 Jul; 14(4):396-411. PubMed ID: 8843541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
    Risitano AM
    Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria.
    Shichishima T; Noji H
    Hematology; 2002 Aug; 7(4):211-27. PubMed ID: 14972783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor.
    Parker CJ; Stone OL; Bernshaw NJ
    J Immunol; 1989 Jan; 142(1):208-16. PubMed ID: 2909615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paroxysmal nocturnal hemoglobinuria.
    Parker CJ
    Curr Opin Hematol; 2012 May; 19(3):141-8. PubMed ID: 22395662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
    Sicre de Fontbrune F; Peffault de Latour R
    Semin Hematol; 2018 Jul; 55(3):124-129. PubMed ID: 30032748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
    Ninomiya H; Kobayashi T; Abe T
    Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation and quantification of complement-sensitive red cells in PNH and aplastic anemia-PNH syndrome].
    Shichishima T; Terasawa T; Uchida T; Kariyone S
    Rinsho Ketsueki; 1989 Mar; 30(3):297-302. PubMed ID: 2769953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
    Varela JC; Brodsky RA
    Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paroxysmal nocturnal hemoglobinuria as a molecular disease.
    Rosse WF
    Medicine (Baltimore); 1997 Mar; 76(2):63-93. PubMed ID: 9100736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling complement-driven diseases in transgenic mice: Values and limitations.
    Ueda Y; Gullipalli D; Song WC
    Immunobiology; 2016 Oct; 221(10):1080-90. PubMed ID: 27371974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of paroxysmal nocturnal hemoglobinuria clonal dominance: possible roles of different apoptosis and CD8+ lymphocytes in the selection of paroxysmal nocturnal hemoglobinuria clones.
    Kunyaboon R; Wanachiwanawin W; U-Pratya Y; Thedsawad A; Taka O
    Hematol Oncol Stem Cell Ther; 2012; 5(3):138-45. PubMed ID: 23095789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recent advances in research on paroxysmal nocturnal hemoglobinuria].
    Kinoshita T
    Rinsho Ketsueki; 1993 May; 34(5):529-36. PubMed ID: 8315823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - reagent selection and assay optimization for high-sensitivity testing.
    Sutherland DR; Illingworth A; Marinov I; Ortiz F; Andreasen J; Payne D; Wallace PK; Keeney M
    Cytometry B Clin Cytom; 2018 Jan; 94(1):23-48. PubMed ID: 29236353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical features and diagnosis of paroxysmal nocturnal hemoglobinuria: correlates with the deficiency of GPI-anchored membrane proteins].
    Ninomiya H
    Rinsho Ketsueki; 1994 Apr; 35(4):352-7. PubMed ID: 7518013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances of studies on pathogenesis and management of paroxysmal nocturnal hemoglobinuria].
    Xu XX; Yang JW; Lu XC; Liu LH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):530-5. PubMed ID: 23628070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Altered metabolism of membrane glycosphingolipids in erythrocytes of paroxysmal nocturnal hemoglobinuria].
    Nakakuma H; Kawaguchi T
    Rinsho Ketsueki; 1991 Jun; 32(6):606-11. PubMed ID: 1890736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia--A possible role of high endogenous IL-2 in their suppression.
    Nissen C; Tichelli A; Gratwohl A; Warthmann C; Moser Y; dalle Carbonare V; Sendelov S; Chklovskaia E; Jansen W; Wodnar-Filipowicz A; Sadallah S; Speck B
    Acta Haematol; 1999; 101(4):165-72. PubMed ID: 10436296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.